Expert recommendations for diagnosis and treatment of cow’s milk protein allergy in the Colombian pediatric population

María Catalina Bagés M., MD, 1* Carlos Fernando Chinchilla M., MD, 2 Catalina Ortiz P., MD, 3 Clara Eugenia Plata G., MD, 4 Enilda Martha Puello M., MD, 5 Óscar Javier Quintero H., MD, 6 Juan Pablo Riveros L., MD, 7 Francisco Javier Sosa G., MD, 8 Alejandra Wilches L., MD, 9 José Fernando Vera-Chamorro, MD. 10

Abstract
Objective: The objective of this paper is to develop and present recommendations for diagnosis and treatment of Cow’s Milk Protein Allergy (CMPA) which can serve as a reference for pediatric and primary care physicians to consult. Materials and methods: This expert position document was developed by a group of doctors who are specialists in several therapeutic areas who have experience in CMPA. The most relevant topics were defined and a review of the available scientific literature was carried out to prepare a proposal for recommendations that was then discussed by the authors. Results: A position paper was developed that proposes a practical approach to definition, diagnosis and treatment of CMPA in pediatric patients. Conclusions: Early diagnosis and proper management of CMPA can help decrease the burden of this disease and its complications.

Keywords
Cow’s milk protein allergy (CMPA), atopy, breastfeeding, infant formulas, hydrolyzed formulas, atopic dermatitis, infants.

INTRODUCTION

Cow’s milk protein allergy (CMPA) is a clinical condition whose origin is immunological origin. It begins at an early age and is the most frequent food allergy from the first months of life through preschool ages. During the first year of life, cow’s milk protein (CMP) is usually the first antigen faced by children fed breast milk or infant formulas. (1, 2)

CMPA has become an important health problem due to its clinical manifestations and their consequences. It is likely that CMPA is associated with development of other types of allergies such as asthma, atopic dermatitis, and rhinitis. (1, 2)

The incidence and prevalence of CMPA is difficult to establish, validate, and compare, given factors such as the small number of epidemiological studies, deficiencies or inconsistencies in study designs, and lack of standardization in methods of diagnosis (self-reporting, challenge tests, levels of specific immunoglobulin E [IgE], skin prick tests, and others). Also, the data reported often only relates
to rapid reactions and does not include late hypersensitive reactions. Furthermore, much available data relates to food allergies other than CMPA. Indeed, reports resulting from surveys (self-reporting) may include erroneous diagnoses (intolerance) and simply report children’s dislikes. In addition, manifestations of CMPA are not necessarily gastrointestinal.

According to EuroPrevall, a European study, the incidence of CMPA is 1% to 4%, but it decreases to 1% to 2% in more specific studies. (3) In the United States of America, reviews published in 2007 and 2010 found that CMPA’s prevalence was 3%. These results are not from specific studies such as skin prick tests or CMPA challenges which report prevalences between 0.6% and 1.0%. In general, the prevalence may be approximately 1%. (4, 5)

Specific reports of the CMPA in Latin America are scarce. According to figures reported by Ávila Castañón et al., the prevalence of milk allergy determined by skin prick tests in patients from the Hospital Infantil de México was 7.7%. In Chile, Martínez reported CMPA prevalences between 2.5 and 7.1% (skin prick test). Reported prevalences depend on the type of study (survey, skin prick test, specific IgE, radioallergosorbent test [RAST]). (6, 7)

Epidemiological information on CMPA in Colombia is scarce. According to survey results published by Marrugo, the prevalence of CMPA in children aged one to eight years is 2.5%, while that for children between 9 and 16 years old is 11.1%. (8) According to Acevedo, the prevalence of CMPA in children under two years of age is 1.8%. (9) The results of these studies cannot be considered to conclusively represent the Colombian population in general. (8-12)

Gastrointestinal manifestations of CMPA are not specific and may be confused with those of gastroesophageal reflux disease (GERD), functional gastrointestinal disorders, lactose intolerance, and food reactions of non-allergic origin. This scenario results in a high probability of over diagnosis or underdiagnosis.

Consequently, early and correct diagnosis of CMPA is a challenge that makes it more difficult for physicians to establish timely and appropriate management of the disease, improve prognoses of patients and minimize CMPA’s burden. In response to these situations, a group of doctors with experience and knowledge regarding CMPA met to develop this position paper. It proposes a practical approach to definition, diagnosis and treatment of CMPA in pediatric patients.

MATERIALS AND METHODS

The recommendations in this document are based on our review of the best quality scientific literature available on CMPA and on the experience of a group of medical specialists in various areas of pediatrics (allergists, gastroenterologists, nutritionists and clinical epidemiologists), from different regions of Colombia. After reviewing the literature, the experts met, recommendations were discussed, and agreement was reached.

RECOMMENDATIONS

Definitions

- **Atopy** is an individual’s genetic predisposition to producing high amounts of IgE before specific antigens. (1, 13)

- **Food intolerance** is an adverse reaction to a type of food that is not related to an immune mechanism. Lactose intolerance is an example. It is not immunologically mediated but is caused by functional deficiency of the enzyme lactase (β-galactosidase) which results in incomplete absorption of lactose. (1, 13)

- **An allergy** is a hypersensitivity reaction mediated by specific immunological mechanisms. In most children, this condition is mediated by IgE. Its phenotypic expression is atopy with or without atopic eczema, allergic rhinitis, or asthma. Other children have gastrointestinal manifestations not mediated by IgE (cell mediated). These are frequent symptoms of the disease. (14)

- **Cow’s milk protein allergy** (CMPA) is a hypersensitivity reaction mediated by specific and reproducible immunological mechanisms. It causes adverse clinical manifestations. The immune reaction can be IgE-mediated, not IgE-mediated, or mixed. It is an allergy to epitopes of protein origin. (1, 13, 14)

CLINICAL DIAGNOSIS

Risk Factors

Risk factors associated onset of CMPA include a mother who smokes, atopic parents and/or siblings, cesarean birth, milk formula in the first days of life, breastfeeding for less than 3 months, a mother over the age of 30, prematurity, and hyperbilirubinemia (Table 1). (1, 15-20)

Clinical Manifestations

Clinical manifestations of CMPA can occur at any age. The following factors should be investigated in patients suspected of CMPA. (1, 14, 21)

**Immediate IgE-mediated symptoms**

Immediate IgE-mediated symptoms develop within minutes of exposure to an allergen. Their severity ranges from mild to severe, and they can involve the skin (urticaria, angioedema), the gastrointestinal tract (vomiting, entero-
colitis), the respiratory system (wheezing, stridor, dyspnea) and the cardiovascular system (Table 2). In young infants, symptoms may be nonspecific including paleness and adynamia. (22-24)

**Table 1.** Factors to consider when CMPA is suspected.

<table>
<thead>
<tr>
<th>Age at onset</th>
<th>Nature of symptoms</th>
<th>Frequency of manifestations</th>
<th>Time between intake and onset of symptoms.</th>
<th>Amount of milk needed to cause symptoms</th>
<th>Milk preparation method</th>
<th>Reproducibility of reaction</th>
<th>Time interval since last reaction</th>
<th>Food diary</th>
<th>Influence of external factors on reaction (e.g. exercise, hormonal changes, stress)</th>
<th>Evaluation of physical growth (length or height and weight)</th>
<th>Early feeding details (duration of breastfeeding, use of substitutes, ablation)</th>
<th>Effect of elimination diets (soy, therapeutic formulas, maternal diet during lactation)</th>
<th>Therapeutic interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Modified from reference 14

**Table 2.** Other immediate IgE-mediated symptoms.

<table>
<thead>
<tr>
<th>Cutaneous</th>
<th>Gastrointestinal</th>
<th>Respiratory</th>
<th>Cardiovascular</th>
<th>General</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pruritus without skin lesions, urticaria, angioedema, exacerbation of atopic eczema</td>
<td>Vomiting, diarrhea, rectal bleeding, gastroesophageal reflux, abdominal pain</td>
<td>Rhinitis, nasal congestion, wheezing, coughing, stridor, respiratory distress</td>
<td>Hypotension/shock</td>
<td>Hypotonia/shock, anaphylaxis, prostration, irritability, failure to thrive</td>
</tr>
</tbody>
</table>

Modified from reference 24

Anaphylaxis, an immediate symptom defined as a systemic or generalized severe allergic reaction, constitutes the most critical manifestation of immediate CMPA. Its mortality rate is nearly 10%. (1, 25-27)

**Late symptoms which are not mediated by IgE or mixed**

Late symptoms occur several hours or days after ingestion of an allergen (Table 3), predominantly involve the gastrointestinal tract, but are almost always multiple. (2, 14, 19, 28, 29)

The most common late gastrointestinal symptoms include vomiting, irritability (colic), dysphagia, diarrhea, constipation, growth failure, and rectal bleeding.

**Table 3.** Late symptoms (not mediated by IgE or mixed mediation)

<table>
<thead>
<tr>
<th>Skin manifestations</th>
<th>Atopic dermatitis, urticaria, angioedema</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastrointestinal manifestations</td>
<td>Nausea, vomiting, anorexia, dysphagia, regurgitation, colic, anorexia, diarrhea, constipation, blood in stool, fecal impaction, gastroesophageal reflux</td>
</tr>
<tr>
<td>Respiratory manifestations</td>
<td>Rhinorrhea, wheezing, chronic coughing</td>
</tr>
<tr>
<td>General</td>
<td>Anaphylaxis</td>
</tr>
</tbody>
</table>

Modified from references 2, 14, 19, 28 and 29

In addition to diagnoses based on symptoms, clinical diagnoses can also be made through the elimination of milk and its derivatives (or elimination of all foods containing dairy ingredients), through food challenge protocols, or through double-blind tests with controls receiving placebos. The reference treatment for clinical diagnosis is elimination of CMP for two to four weeks followed by reintroduction of CMP in the form of an open challenge or a blind challenge. (18, 20)

**Differential Diagnosis**

It is important to consider other entities that could be confused with CMPA. These include lactose intolerance, renal tubular acidosis, pyloric hypertrophy, cystic fibrosis or enterocolitis, and gastroesophageal reflux disease.

**Recommendations**

- It is essential to prepare a clinical history that includes CMPA risk factors to establish an early diagnosis.
- Before diagnosing a new allergy or multiple allergies, it should be considered that a patient may have been exposed to hidden derivatives of milk or traces of milk in food.
- Except for gastrointestinal allergies, most milk-induced allergic symptoms develop within minutes or hours after ingestion.
- Classical, CMPA signs and symptoms present in the skin, the gastrointestinal tract and the respiratory tract.
- A differential diagnosis of CMPA must be made.
- Changes in gut microbiota are partly responsible for increasing cases of allergic diseases. Ideally, improvement of intestinal microbiota should start at birth with vaginal delivery and be followed by initiation of breast milk in the first hour of life and avoidance of indiscriminate use of antibiotics to reduce the risk of CMPA symptoms. (30, 31)

**DIAGNOSIS: CLINICAL, LABORATORY AND IMMUNOLOGICAL TESTS**

The management of each patient must be individualized and based on use of various diagnostic resources.
Diagnostic Tests

- Oral food challenge tests are the reference treatment for diagnosis of CMPA. These tests must be done by either a gastroenterologist or an allergist. Challenge testing is not recommended if the physician does not have the experience and knowledge necessary to ensure patient safety. Oral challenge tests with cow’s milk are in vivo and used to definitively confirm a preliminary suspicion of CMPA.

- A test that results in a clinical reaction is defined as a positive or failed challenge, whereas a test without clinical reaction is called a negative or approved challenge. Thus, a positive challenge will indicate the tolerated dose, if any, and will allow planning of partial or complete CMP exclusion diets. (14, 18, 20)

- Basic blood tests should include a peripheral blood smear, a ferritin test, and total and differential proteins.

- Every patient requires a complete nutritional evaluation to detect nutritional risks of consuming allergens.

- Skin tests have high sensitivity and negative predictive value but low specificity. They can confirm sensitization but cannot diagnose whether a patient has CMPA.

- Specific IgE level cut-off points of more than five KU/L within one year and more than 15 KU/L in more than one year have been established specifically for cow’s milk with 95% probability when an exposure test is positive. (14)

- Skin sensitization tests are not recommended for patients with any food allergy, especially those mediated by IgE. (14)

Recommendations

Most patients seen in pediatric clinics present non-IgE-mediated processes and do not require immunological diagnostic tests.

- The following tests are requested for patients suspected of CMPA whose clinical pictures are compatible with IgE-mediated or mixed reactions and for patients with manifestations of reactions not mediated by IgE who do not respond to treatment: Specific IgE (RAST test or ImmunoCAP) and a skin prick test for cow’s milk. After testing patients can be referred to a pediatric gastroenterologist or allergist.

- Evaluation of total serum IgE is not recommended for these patients.

- Delayed reactions do not have conventional diagnostic tests so diagnosis is clinical by exclusion and challenge.

- A negative response to immunological tests does not rule out a process that is not mediated by IgE.

DIGESTIVE ENDOSCOPY DIAGNOSIS

A patient’s symptoms are the most important factors to consider when considering an endoscopic evaluation of a patient with CMPA regardless of age. Especially important are suspicion of eosinophilic esophagitis, allergic proctocolitis with anemic and persistent manifestations other than bleeding, abdominal bloating and persistent vomiting (which may have a mixed component). (32-34)

Indications for Upper and Lower Gastrointestinal Endoscopy in patients with CMPA

Endoscopic tests are not usual for patients diagnosed with CMPA since the diagnosis is clinical. Therefore, the decision to carry out these tests is based on well-defined clinical criteria based on patient characteristics, nutritional status, laboratory tests and evident clinical manifestations. Indications for digestive endoscopy are listed in Table 4. (35, 36)

Table 4. Indications for digestive endoscopy

| Signs of malabsorption, microscopic or macroscopic nutrient deficiency, insufficient weight gain, malnutrition, suspicion of eosinophilic gastroenteropathy |
| Anemia and hypoalbuminemia in allergic patients |
| Persistent abdominal pain, bloating, and hyporexia |
| Persistent loss of appetite and suspicion of eosinophilic esophagitis |
| Upper or lower digestive tract bleeding |
| Diagnosis of FPIES |
| Suspected inflammatory bowel disease |
| Monitoring during treatment or after treatment (e.g. eosinophilic esophagitis) |

FPIES: Food Protein-Induced Enterocolitis Syndrome. Modified from references 35 and 36.

Indications for endoscopy in patients with processes not mediated by IgE are listed in Table 5.

Endoscopic Findings Suggestive of CMPA

Endoscopic findings are nonspecific and on several occasions do not aid in the diagnosis of CMPA-induced proctocolitis. Endoscopic findings suggestive of allergy, mainly when eosinophilic esophagitis is suspected, include linear grooves (33-48%), circular rings (44-55%), alteration of the vascular pattern (41%), whitish papules (27%), partial stenosis (10-39%) and complete stenosis (9%).

Endoscopy results are normal in 7% to 32% of cases. Even when endoscopic findings are normal, proximal and distal biopsies of the esophagus should be taken from the antrum.
and corpus of in the stomach, the duodenal bulb, the ileum, colon, cecum and all quadrants to look for eosinophilic gastroenteropathy, celiac disease, Helicobacter pylori and other pathologies. (32-34)

**Table 5.** Indications for referral to a specialist in processes not mediated by IgE *

<table>
<thead>
<tr>
<th>Proctosigmoiditis</th>
<th>Persistent rectal bleeding, accompanied by mucus, anal pain, anal fissures, anal pilomas (skin tag), persistent diarrhea, anemia, failure to thrive</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eosinophilic esophagitis</td>
<td>Hyporexia, intake of plenty of fluids with meals, slow intake and chewing, dysphagia or feeling of clogging, suspicion of esophageal stenosis, failure to thrive</td>
</tr>
<tr>
<td>Eosinophilic gastroduodenitis</td>
<td>Persistent abdominal pain, bloating, vomiting, hematemesis, signs of malabsorption, anemia or nutritional deficiencies, failure to thrive</td>
</tr>
<tr>
<td>Eosinophilic colitis</td>
<td>Persistent diarrhea, abdominal pain and bloating, lower digestive bleeding</td>
</tr>
</tbody>
</table>

*This table contains agreements from the experts’ meeting.

**Recommendations**

- Endoscopic procedures should be performed by experienced pediatric gastroenterologists.
- Biopsies should be taken from the esophagus, stomach, duodenal bulb, duodenum, ileum, cecum, and the quadrants of the colon as well as an eosinophil count by field. The Marsh classification for celiac disease should be used.

**NUTRITIONAL MANAGEMENT**

**Basic Concepts**

Each patient’s nutrition should be managed individually. This requires a multidisciplinary team that includes a nutritionist who is an expert in management of CMPA.

According to *Diagnosis and Rationale for Action against Cow’s Milk Allergy* (DRACMPA), the following issues should be considered:

- Strict nutritional surveillance during the process is a requirement.
- An elimination diet of at least 6 months but less than one year is recommended.
- The elimination diet must be strict, effective and complete. Inhalation of, and skin contact with, products or traces that contain CMP must be avoided.
- All elimination diets must be nutritionally safe. It is necessary to avoid macronutrient and micronutrient restrictions. Other types of food including egg and fish should never be restricted if the diagnosis is CMPA. (14)

**Nutrition Management Objectives**

The objective of nutritional management of patients with CMPA is to maintain adequate nutrition to guarantee the child’s growth and development. (37, 38)

**Formulas**

Factors that should be considered for choosing a formula for patients with CMPA are shown in Table 6. (37, 39)

**Table 6.** Factors to consider when choosing special formulas

<table>
<thead>
<tr>
<th>Nutritional management objectives</th>
<th>Hypoallergenic Formulas</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malnutrition, anemia, hypoalbuminemia</td>
<td>hypoallergenic formulas meet the criteria of 90% clinical tolerance (95% confidence interval in children with proven allergy to CMP). Extensively hydrolyzed formula (EHF) and free amino acid-based formulas (AAF) formulas are two types of hypoallergenic formulas (Table 7).</td>
</tr>
<tr>
<td>Risk of anaphylaxis</td>
<td>Therapeutic Challenges</td>
</tr>
<tr>
<td>Patient’s age</td>
<td>The first challenge should be performed six months to one year after diagnosis in patients with mild symptoms.</td>
</tr>
<tr>
<td>Adherence to dietary restrictions</td>
<td>In cases of anaphylaxis, the challenge should be performed at least 1 year after the episode. Preferably, it should be monitored in a hospital center. This challenge should be prescribed by a competent specialist.</td>
</tr>
</tbody>
</table>

**Hypoallergenic Formulas**

Therapeutic Challenges

- A challenge should not coincide with initiation of complementary feeding in 6 month old children because, if symptoms appear, it will be impossible to determine whether they are due to the complementary feeding or the challenge.

**Recommendations in pregnancy and exclusive breastfeeding**

- There is no evidence that restricting a pregnant woman’s consumption of allergens can prevent the appearance of a CMPA in the baby. Avoid restricting food eaten by the mother during pregnancy and aim for an adequate, varied and balanced diet that maintains recommended weight.
- Exclusive breastfeeding is associated with multiple benefits. Restrictions on on mothers’ consumption of
Read the label on fruit desserts. It is not safe to use equine or goat milk as alternatives. The recommended formulas for infants with CMPA are

- Mothers should be given motivation to continue breastfeeding. Gastrointestinal manifestations improve at 2 weeks and dermatological manifestations improve at 6 weeks after starting CMP restrictions. These manifestations do not constitute a reason to discontinue breastfeeding. If there is no improvement, the mother should be referred to a specialist before breastfeeding is stopped or restricted.
- Complementary feeding can be introduced between four and six months of age. There is an increased risk of allergy if solid foods are introduced before four months. There is no evidence that delaying the introduction of foods considered allergenic (e.g., eggs and strawberries) before the first year reduces the risk of allergy in either the general or atopic population.
- There is no clear evidence that partially hydrolyzed formulas and EHF prevent any type of allergy or that they are better than breast milk.

### Recommendations for children who do not receive breast milk

- The recommended formulas for infants with CMPA are EHF and AAF.
- Children may require supplementation with micronutrients such as calcium (when a minimum volume of 500 mL of breast milk or formula cannot be guaranteed), iron (when there is heavy bleeding or in patients with iron deficiency) and vitamin D (if as deficiency is demonstrated).
- If CMPA persists after the first year, the use of special formulas designed for that age is required.
- There is no evidence in Colombia that hypoallergenic formulas (Confot brand) prevent or treat CMPA.
- The use of drinks made from almonds, rice, coconut and soybeans and others nuts and grains is not recommended given the high probability of cross-reactions and insufficient nutritional value.

### Additional Recommendations

- **Prohibit desserts with butter, milk, casein, or butter-milk** (Table 8). (42-46)
- **Read the label on fruit desserts.**
- **Ban gratin, creamy, breaded and fried foods.**
- **It is not safe to use equine or goat milk as alternatives.**

### PHARMACOLOGICAL MANAGEMENT AND IMMUNOTHERAPY

There is no specific pharmacological treatment for CMPA, but epinephrine is the treatment of choice in cases of severe IgE-mediated allergy such as anaphylaxis.

Adrenaline’s half-life is short and multiple doses may be required. In Colombia, it is only used in hospitals, and there are no autoinjectors. When an anaphylactic reaction occurs, it is recommended to immediately go to an emergency department. The recommended undiluted intramuscular dose for hospital management of anaphylaxis with adrenaline is 0.15 mg for patients weighing less than 25 kg. A 21 short replaceable needle syringe should be used, and

### Table 7. Hypoallergenic formulas

<table>
<thead>
<tr>
<th>Formula Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extensively Hydrolyzed Formulas (EHF)</td>
<td>Protein source is whey or casein. Palatability depends on the type of protein, the degree of hydrolysis and the presence or absence of lactose. EHF are formulas for treatment of CMPA initiated by DRACMPA (Diagnosis and Rationale for Action against Cow’s Milk Allergy). They resolve more than 90% of mild to moderate clinical manifestations. (35, 40) Rice EHF are an alternative when there is no response to other EHF but are not considered a first option. Studies conducted with these formulas are short-term, and it is unclear whether they can trigger rice sensitization.</td>
</tr>
<tr>
<td>Soy formulas (14, 38)</td>
<td>Soy formulas are different from commercial soy-based drinks and are indicated in IgE-mediated CMPA, when there is no response to EHF or AAF. They are not suitable for administration to infants under 6 months of age due to their nutritional composition and the possibility of cross reactions.</td>
</tr>
<tr>
<td>Free Amino Acid Formulas (AAF) (14, 19)</td>
<td>FAAs are recommended when there is no response to EHF, when there are multiple food allergies, and when there are severe CMPA symptoms including anemia, hypoalbuminemia, and/or malnutrition, when symptoms do not improve in an exclusively breastfed patient, and when they do not improve when restrictions are placed on the mother. Most patients respond to a mixed diet. They are also recommended in cases of eosinophilic esophagitis, FPIES, anaphylaxis and Heiner syndrome.</td>
</tr>
</tbody>
</table>

CMPA: Cow’s milk protein allergy; IgE: immunoglobulin E; FPIES: Food Protein-Induced Enterocolitis Syndrome

---

**Revised: 2020**
is not always reached, and it is desirable that there be no severe reaction to accidental exposure (Table 9). (49-51) Treatment implies that the patient continuously receives doses of the allergen. The overall effectiveness of this treatment is 35%.

In summary, oral immunotherapy is more effective than cutaneous immunotherapy, but adverse events occur more frequently with oral immunotherapy than with cutaneous immunotherapy.

### Biological Therapy

Omalizumab, lilizumab, and quilizumab are biologic therapies which are being studied for treatment of CMPA, primarily of the IgE type, and as adjuvants to immunotherapy. (52, 53)

---

**Table 8. Recommendations on restrictions on food consumption**

<table>
<thead>
<tr>
<th>Prohibited food</th>
<th>Acidsified milk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Casein (hydrolyzed)</td>
<td>Chocolate milk</td>
</tr>
<tr>
<td>All caseinates</td>
<td>Butter</td>
</tr>
<tr>
<td>Milk rennet casein</td>
<td>Margarines</td>
</tr>
<tr>
<td>Sour cream</td>
<td>(Read the labels carefully. 100% vegetable margarines can be eaten.)</td>
</tr>
<tr>
<td>Milk cream</td>
<td>Custard</td>
</tr>
<tr>
<td>Curd</td>
<td>Puddings</td>
</tr>
<tr>
<td>Ghee or clarified cow butter without salt</td>
<td>Cheese</td>
</tr>
<tr>
<td>Ice cream</td>
<td>Cottage cheese</td>
</tr>
<tr>
<td>Lactulose</td>
<td>Artificial butter flavoring</td>
</tr>
<tr>
<td>Lactalbumin, lactalbumin phosphate</td>
<td>Nougats</td>
</tr>
<tr>
<td>Lactoferrin</td>
<td>Whey (in any form)</td>
</tr>
<tr>
<td>Lactose</td>
<td>Yogurt (frozen, smooth, regular, fruit and yogurt-based bars)</td>
</tr>
<tr>
<td>Milk in any form (condensed, derived, dried, evaporated, goat’s milk, milk of other animals, low fat, lactose free) malted, fat free, powdered, whole, skimmed</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Foods that may contain milk protein (should be eaten with caution)</th>
<th>Non-dairy products such as frozen desserts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prepared meatballs</td>
<td>Baked products made with butter, dairy products, casein, sodium caseinate or whey protein</td>
</tr>
<tr>
<td>Coffee</td>
<td>Flavors (natural and artificial)</td>
</tr>
<tr>
<td>Candy</td>
<td>Sauces</td>
</tr>
<tr>
<td>Lactic acid cultures (used to prepare homemade yogurt)</td>
<td></td>
</tr>
<tr>
<td>Chocolate</td>
<td></td>
</tr>
<tr>
<td>Sliced ham, chicken or beef</td>
<td></td>
</tr>
<tr>
<td>Hot dogs</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Foods that do not contain cow’s milk protein</th>
<th>Oleoresin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcium lactate</td>
<td></td>
</tr>
<tr>
<td>Cream of tartar</td>
<td></td>
</tr>
<tr>
<td>Coconut milk</td>
<td></td>
</tr>
<tr>
<td>Calcium caseinate</td>
<td></td>
</tr>
<tr>
<td>Lactic serum</td>
<td></td>
</tr>
<tr>
<td>Casein</td>
<td></td>
</tr>
</tbody>
</table>

*Modified from references 42-46.*

---

the shot should be administered in the middle lateral thigh. Repeat the dose in 10 to 15 minutes if there is no response. The dose should be 0.3 mg for patients weighing more than 25 kg (anaphylaxis guideline from the European Academy of Allergy and Clinical Immunology (EAACI)). (47, 48)

In the last decade, other therapies for CMPA including allergen specific immunotherapy, biological therapy, Chinese medicine, probiotics and prebiotics have been investigated.

### Immunotherapy

The objective of immunotherapy is to desensitize the patient by increasing the threshold of reactivity to an allergen, thus generating sustained tolerance for months or years without additional treatment. Nevertheless, this goal is not always reached, and it is desirable that there be no severe reaction to accidental exposure (Table 9). (49-51) Treatment implies that the patient continuously receives doses of the allergen. The first immunotherapy studies in food allergy were made for peanut allergies. The overall effectiveness of this treatment is 35%.

In summary, oral immunotherapy is more effective than cutaneous immunotherapy, but adverse events occur more frequently with oral immunotherapy than with cutaneous immunotherapy.
Chinese Traditional Medicine

Food Allergy Herbal Formulas (FAHF) 1 and 2 consist of a blend of Chinese herbs, the active ingredients of which are berberine and limonine. So far they are experimental treatments and are not currently recommended.

<table>
<thead>
<tr>
<th>Table 9. Types of immunotherapy.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Subcutaneous immunotherapy</strong></td>
</tr>
<tr>
<td><strong>Sublingual immunotherapy</strong></td>
</tr>
<tr>
<td>(liquid extract of the sublingual allergen)</td>
</tr>
<tr>
<td><strong>Oral immunotherapy</strong></td>
</tr>
<tr>
<td><strong>Epicutaneous immunotherapy</strong></td>
</tr>
</tbody>
</table>

CMAPA: Cow’s milk protein allergy; CMP: cow’s milk protein; FDA: Food and Drug Administration. Modified from references 49-51

Financial Support

We thank Danone Baby Nutrition Colombia for its support. It did not interfere in the discussions, decisions, or in academic opinions adopted.

REFERENCES


Probiotics and Prebiotics

There is still no conclusive evidence that probiotics and prebiotics are effective treatments of CMPA or that administration during the last trimester of pregnancy and the first months of breastfeeding prevents CMPA. The data suggests that supplementing hydrolyzed formulas with certain strains of probiotics may have benefits in terms of oral tolerance, primarily in atopic eczema. However, additional research is required to define species, dosage, and therapy times. The 2016 World Allergy Organization (WAO) guideline suggests the use of probiotics exclusively in children who are not breastfed. (40, 54)

Gene Therapy

Research about gene therapy for CMPA is ongoing, but as of yet there are no approved therapies.

Recommendations

- Elimination diets continue to be the treatment of choice for CMPA.
- Immunotherapy is the most promising treatment in the near future.
- Other adjuvant therapies appear to improve the efficacy of immunotherapy and decrease adverse effects, but evidence is still insufficient to recommend them.

Chinese Traditional Medicine

Food Allergy Herbal Formulas (FAHF) 1 and 2 consist of a blend of Chinese herbs, the active ingredients of which are berberine and limonine. So far they are experimental treatments and are not currently recommended.
47. European Academy of Allergy and Clinical Immunology (EAACI). Food Allergy and Anaphylaxis Guidelines. Zürich: EAACI; 2014.